A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma
- PMID: 7519046
- DOI: 10.1002/gcc.2870090404
A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma
Abstract
Activation of the RET protooncogene tyrosine kinase (tk) by fusion with other genes is a frequent finding in papillary thyroid carcinoma. The tk domain of proto-RET can be fused either with the D10S170 gene generating the RET/PTC1 transforming sequence or with sequences belonging to the gene encoding the regulatory subunit RIA of c-AMP-dependent protein kinase A, thus forming the RET/PTC2 oncogene. We have previously shown that an inversion of chromosome 10, inv(10)(q11.2q21), is responsible for the generation of the RET/PTC1. Here we report that a chromosomal translocation, t(10;17)(q11.2;q23), juxta-poses the tk domain of the RET protooncogene, which resides on chromosome 10, to a 5' portion of the RIA gene on chromosome 17, leading to the formation of the chimeric transforming gene RET/PTC2. The finding of the transforming protein in primary tumor cell extracts supports the conclusion that RET/PTC2 activation plays a role in papillary thyroid tumorigenesis.
Similar articles
-
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.Cancer Res. 1994 Jun 1;54(11):2979-85. Cancer Res. 1994. PMID: 8187085
-
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.Mol Cell Biol. 1993 Jan;13(1):358-66. doi: 10.1128/mcb.13.1.358-366.1993. Mol Cell Biol. 1993. PMID: 7678053 Free PMC article.
-
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene. 1994 Feb;9(2):509-16. Oncogene. 1994. PMID: 8290261
-
[Rearrangement of the RET gene in papillary thyroid carcinoma].Wiad Lek. 2001;54 Suppl 1:64-71. Wiad Lek. 2001. PMID: 12182064 Review. Polish.
-
The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.Virchows Arch. 1997 Jul;431(1):1-9. doi: 10.1007/s004280050062. Virchows Arch. 1997. PMID: 9247627 Review.
Cited by
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Influencers on Thyroid Cancer Onset: Molecular Genetic Basis.Genes (Basel). 2019 Nov 8;10(11):913. doi: 10.3390/genes10110913. Genes (Basel). 2019. PMID: 31717449 Free PMC article. Review.
-
Investigation of the clonal origin of multifocal papillary thyroid carcinoma according to the X-chromosome inactivation pattern.Oncol Lett. 2019 May;17(5):4695-4700. doi: 10.3892/ol.2019.10105. Epub 2019 Mar 4. Oncol Lett. 2019. PMID: 30944656 Free PMC article.
-
Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.J Exp Clin Cancer Res. 2018 Apr 17;37(1):84. doi: 10.1186/s13046-018-0746-y. J Exp Clin Cancer Res. 2018. PMID: 29665843 Free PMC article.
-
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Mol Cell Biol. 2014 May;34(10):1722-32. doi: 10.1128/MCB.01592-13. Epub 2014 Feb 24. Mol Cell Biol. 2014. PMID: 24567371 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
